Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1984 Sep;47(9):960–964. doi: 10.1136/jnnp.47.9.960

Does viloxazine have epileptogenic properties?

J G Edwards, M Glen-Bott
PMCID: PMC1027998  PMID: 6434699

Abstract

Six cases of convulsive seizures occurring during treatment with viloxazine notified to the Committee on Safety of Medicines (CSM) and two other cases from Japan were reviewed. A critical study of the patient's histories suggests a possible causal connection between drug and seizures in only two of these cases. The occurrence of convulsions is not in keeping with the results of animal experiments and of clinical trials in which epileptic patients were included, both of which suggest that viloxazine does not have epileptogenic properties and may have anticonvulsant actions. A worldwide review of clinical trials in which unwanted effects have been recorded suggests that viloxazine, even if possessing convulsive properties like other anti-depressants, is probably less epileptogenic than conventional tricyclics and is not contraindicated in epileptic patients requiring antidepressant medication.

Full text

PDF
960

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alkalay D., Wagner W. E., Jr, Carlsen S., Khemani L., Volk J., Bartlett M. F., LeSher A. Bioavailability and kinetics of maprotiline. Clin Pharmacol Ther. 1980 May;27(5):697–703. doi: 10.1038/clpt.1980.99. [DOI] [PubMed] [Google Scholar]
  2. Dunlop D. The use and abuse of psychotrophic drugs. Scott Med J. 1971 Aug;16(8):345–349. doi: 10.1177/003693307101600803. [DOI] [PubMed] [Google Scholar]
  3. Edwards J. G., Alexander J. R., Alexander M. S., Gordon A., Zutchi T. Controlled trial of sulpiride in chronic schizophrenic patients. Br J Psychiatry. 1980 Dec;137:522–529. doi: 10.1192/bjp.137.6.522. [DOI] [PubMed] [Google Scholar]
  4. Edwards J. G. Antidepressants and convulsions. Lancet. 1979 Dec 22;2(8156-8157):1368–1369. doi: 10.1016/s0140-6736(79)92852-6. [DOI] [PubMed] [Google Scholar]
  5. Edwards J. G. Convulsive seizures and viloxazine. Br Med J. 1977 Jul 9;2(6079):96–97. doi: 10.1136/bmj.2.6079.96-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Edwards J. G. Viloxazine: assessment of potential rapid antidepressant action. Br Med J. 1977 Nov 19;2(6098):1327–1327. doi: 10.1136/bmj.2.6098.1327. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fontan M., Goudemand M., Pellerin-Millecamps E. Expérimentation clinique de la viloxazine dans les états dépressifs. Encephale. 1979;5(3):243–249. [PubMed] [Google Scholar]
  8. Hollister L. E. Valium: a discussion of current issues. Psychosomatics. 1977;18(1):44–58. doi: 10.1016/S0033-3182(77)71104-1. [DOI] [PubMed] [Google Scholar]
  9. Inman W. H., Vessey M. P. Investigation of deaths from pulmonary, coronary, and cerebral thrombosis and embolism in women of child-bearing age. Br Med J. 1968 Apr 27;2(5599):193–199. doi: 10.1136/bmj.2.5599.193. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Jick H., Dinan B. J., Hunter J. R., Stergachis A., Ronning A., Perera D. R., Madsen S., Nudelman P. M. Tricyclic antidepressants and convulsions. J Clin Psychopharmacol. 1983 Jun;3(3):182–185. [PubMed] [Google Scholar]
  11. Magnus R. V. A placebo controlled trial of viloxazine with and without tranquillizers in depressive illness. J Int Med Res. 1975;3(3):207–213. doi: 10.1177/030006057500300311. [DOI] [PubMed] [Google Scholar]
  12. Mallion K. B., Todd A. H., Turner R. W., Bainbridge J. G., Greenwood D. T., Madinaveitia J., Somerville A. R., Whittle B. A. 2-(2-ethoxyphenoxymethyl)tetrahydro-1,4-oxazine hydrochloride, a potential psychotropic agent. Nature. 1972 Jul 21;238(5360):157–158. doi: 10.1038/238157a0. [DOI] [PubMed] [Google Scholar]
  13. Meldrum B. S., Anlezark G. M., Adam H. K., Greenwood D. T. Anticonvulsant and proconvulsant properties of viloxazine hydrochloride: pharmacological and pharmacokinetic studies in rodents and the epileptic baboon. Psychopharmacology (Berl) 1982;76(3):212–217. doi: 10.1007/BF00432547. [DOI] [PubMed] [Google Scholar]
  14. Neal H., Bradley P. B. Electrocortical changes in the encéphale isolé cat following chronic treatment with antidepressant drugs. Neuropharmacology. 1979 Jul;18(7):611–615. doi: 10.1016/0028-3908(79)90113-8. [DOI] [PubMed] [Google Scholar]
  15. Neal H., Bradley P. B. Electrophysiological studies with a new anti-depressant drug: comparison of the effects of viloxazine (ICI 58,834) with three tricyclic anti-depressants in the encéphale isolé. Neuropharmacology. 1978 Oct;17(10):835–849. doi: 10.1016/0028-3908(78)90072-2. [DOI] [PubMed] [Google Scholar]
  16. Peck A. W., Stern W. C., Watkinson C. Incidence of seizures during treatment with tricyclic antidepressant drugs and bupropion. J Clin Psychiatry. 1983 May;44(5 Pt 2):197–201. [PubMed] [Google Scholar]
  17. Tartara A., Bo P., Maurelli M., Savoldi F., Manzo L. EEG profile of the anticonvulsant action of viloxazine in the rabbit. Farmaco Sci. 1983 Mar;28(3):161–166. [PubMed] [Google Scholar]
  18. Weissman M. M., Klerman G. L. Sex differences and the epidemiology of depression. Arch Gen Psychiatry. 1977 Jan;34(1):98–111. doi: 10.1001/archpsyc.1977.01770130100011. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES